 Ursodeoxycholic Acid
"Ursodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
| Descriptor ID |
D014580
|
| MeSH Number(s) |
D04.210.500.105.225.272.962 D04.210.500.221.430.342.925
|
| Concept/Terms |
Ursodeoxycholic Acid- Ursodeoxycholic Acid
- Acid, Ursodeoxycholic
- Ursacholic Acid
- Acid, Ursacholic
- 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
- 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid
- Ursodiol
- Deoxyursocholic Acid
- Acid, Deoxyursocholic
|
Below are MeSH descriptors whose meaning is more general than "Ursodeoxycholic Acid".
Below are MeSH descriptors whose meaning is more specific than "Ursodeoxycholic Acid".
This graph shows the total number of publications written about "Ursodeoxycholic Acid" by people in this website by year, and whether "Ursodeoxycholic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ursodeoxycholic Acid" by people in Profiles.
-
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladr?n de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 08 01; 78(2):397-415.
-
Kowdley KV, Forman L, Eksteen B, Gunn N, Sundaram V, Landis C, Harrison SA, Levy C, Liberman A, Di Bisceglie AM, Hirschfield GM. A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis. Am J Gastroenterol. 2022 11 01; 117(11):1805-1815.
-
Manni ML, Heinrich VA, Buchan GJ, O'Brien JP, Uvalle C, Cechova V, Koudelka A, Ukani D, Rawas-Qalaji M, Oury TD, Hart R, Ellgass M, Mullett SJ, Fajt ML, Wenzel SE, Holguin F, Freeman BA, Wendell SG. Nitroalkene fatty acids modulate bile acid metabolism and lung function in obese asthma. Sci Rep. 2021 09 07; 11(1):17788.
-
Deneau MR, Mack C, Mogul D, Perito ER, Valentino PL, Amir AZ, DiGuglielmo M, Draijer LG, El-Matary W, Furuya KN, Gupta N, Hochberg JT, Horslen S, Jensen MK, Jonas MM, Kerkar N, Koot BGP, Laborda TJ, Lee CK, Loomes KM, Martinez M, Miethke A, Miloh T, Mohammad S, Ovchinsky N, Rao G, Ricciuto A, Sathya P, Schwarz KB, Shah U, Singh R, Vitola B, Zizzo A, Guthery SL. Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis. Hepatology. 2021 03; 73(3):1061-1073.
-
Gao RY, Shearn CT, Orlicky DJ, Battista KD, Alexeev EE, Cartwright IM, Lanis JM, Kostelecky RE, Ju C, Colgan SP, Fennimore BP. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis. Mucosal Immunol. 2021 03; 14(2):479-490.
-
Bowlus CL, Pockros PJ, Kremer AE, Par?s A, Forman LM, Drenth JPH, Ryder SD, Terracciano L, Jin Y, Liberman A, Pencek R, Iloeje U, MacConell L, Bedossa P. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2020 05; 18(5):1170-1178.e6.
-
Deneau M, Perito E, Ricciuto A, Gupta N, Kamath BM, Palle S, Vitola B, Smolka V, Ferrari F, Amir AZ, Miloh T, Papadopoulou A, Mohan P, Mack C, Kolho KL, Iorio R, El-Matary W, Venkat V, Chan A, Saubermann L, Valentino PL, Shah U, Miethke A, Lin H, Jensen MK. Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course. J Pediatr. 2019 06; 209:92-96.e1.
-
Narkewicz MR. Cystic Fibrosis Liver Disease and Ursodeoxycholic Acid: One Small Step Forward, Miles to Go. J Pediatr. 2016 10; 177:17-18.
-
Leung DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR. Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr. 2015 Oct; 167(4):862-868.e2.
-
Ashraf I, Choudhary A, Arif M, Matteson ML, Hammad HT, Puli SR, Bechtold ML. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol. 2012 Apr; 31(2):69-74.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|